Show simple item record

dc.contributor.authorNgilirabanga, J.B.
dc.contributor.authorSamsodien, H.
dc.date.accessioned2021-09-07T20:17:26Z
dc.date.available2021-09-07T20:17:26Z
dc.date.issued2020
dc.identifier.citationNgilirabanga, Jean & Samsodien, Halima. (2021). Pharmaceutical co‐crystal: An alternative strategy for enhanced physicochemical properties and drug synergy. Nano Select. 2. 10.1002/nano.202000201.en_US
dc.identifier.issn2688-4011
dc.identifier.uri10.1002/nano.202000201
dc.identifier.urihttp://hdl.handle.net/10566/6623
dc.description.abstractA growing number of co-crystals in the literature are proof of how significant the co-crystallization concept has become. Co-crystallization enhances physicochemical properties through the formation of intermolecular interactions between a drug and a co-former. A co-crystal is a single crystalline material consisting of at least two molecular components solid at room temperature and present in a definite stoichiometric ratio. Pharmaceutical co-crystals consist of the active pharmaceutical ingredient and the co-former selected from generally regarded as safe (GRAS) list of the United State Food and Drug Administration.en_US
dc.language.isoenen_US
dc.publisherWiley Open Accessen_US
dc.subjectCo-crystal developmenten_US
dc.subjectCo-crystallizationen_US
dc.subjectDesignen_US
dc.subjectPharmaceutical co-crystalsen_US
dc.subjectSynergistic co-crystalsen_US
dc.titlePharmaceutical co-crystal: An alternative strategy for enhanced physicochemical properties and drug synergyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record